View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAmur Minerals 過去の業績過去 基準チェック /06Amur Minerals は平均年間 6.4% の収益成長を遂げていますが、Metals and Mining 業界では年間 減少率 となっています。9.4% です。主要情報6.39%収益成長率27.03%EPS成長率Metals and Mining 業界の成長26.40%収益成長率n/a株主資本利益率-62.88%ネット・マージンn/a前回の決算情報30 Jun 2023最近の業績更新お知らせ • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024すべての更新を表示Recent updatesお知らせ • Mar 31CRISM Therapeutics Corporation Provides Positive Update Regarding Its Clinical Trial Authorisation ApplicationCRISM Therapeutics Corporation provided a positive update regarding its clinical trial authorisation application to evaluate irinotecan ChemoSeed in patients with high grade glioma. CRISM has been working with the Medicines and Healthcare products Regulatory Agency to finalise the design of the first in-human trial of ChemoSeed and is pleased to confirm it has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed. The written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately PS400,000 to conduct the toxicology studies. In addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in first quarter 2025 and to begin clinical trials of ChemoSeed in fourth quarter 2025, subject to MHRA and other external regulatory organizations meeting expected review times. The Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify.お知らせ • Mar 28CRISM Therapeutics Corporation Announces Grant Awarded by Innovate UKCRISM Therapeutics Corporation announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the "Project"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas. The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology ("docetaxel ChemoSeed") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment. Docetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect. The Project, which will take about 12 months, is designed to deliver: A functional prototype of the implantable device; Pre-clinical validation data demonstrating safety and efficacy; IP protection through patents for core innovations; Scalable manufacturing protocols for commercialisation. The outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy. The total cost of the Project is £152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of £96,106, which represents 63% of the total cost. The remaining £56,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed.お知らせ • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024お知らせ • May 15Amur Minerals Corporation, Annual General Meeting, May 29, 2024Amur Minerals Corporation, Annual General Meeting, May 29, 2024. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdomお知らせ • Nov 13Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023, at 10:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdomお知らせ • Sep 25Amur Minerals Corporation Announces Special DividendAmur Minerals Corporation announced to pay a one-time special dividend of 1.8 pence per ordinary share within 90 days of receipt of the completion payment.お知らせ • Sep 07Amur Minerals Announces Suspension of Trading on AIMAmur Minerals Corporation confirmed that trading in the Company's shares on AIM will be suspended with effect from 7.30 a.m. BST 7 September 2023. As stated in the Company's notification of 6 March 2023, following the disposal of the Company's AO Kun-Manie subsidiary, Amur became classified as an AIM Rule 15 cash shell from that date, and as such was required to make an acquisition or acquisitions which would constitute a reverse takeover under Rule 14 of the AIM Rules for Companies, or be re-admitted on AIM as an investing company under the AIM Rules on or before the date falling six months from 6 March 2023. As neither a reverse takeover nor readmission to trading on AIM as an investing company have been completed, trading in the Company's shares on AIM will now be suspended on7 September 2023. Trading will remain suspended until the completion of a reverse takeover, which requires the publication of an admission document and the approval of such a transaction at a General Meeting of the Company, or the Company is readmitted to trading on AIM as an investing company. If no such transaction is completed within six months, the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41. There can be no assurance that the Company will be able to complete a reverse takeover during the six-month suspension period. The board of Amur continues to review a number of reverse takeover opportunities. Further announcements will be made as appropriate.お知らせ • Aug 10Amur Minerals Corporation Announces Cessation of Discussions with Ascent Resources PlcAscent Resources Plc (AIM:AST) ("Ascent" or, the "Company"), noted Amur Minerals Corporation (AIM:AMC) ("Amur") announcement, regarding the cessations of discussions regarding thenon-binding indicative proposal of a possible share offer for the entire issued and to be issued share capital of Amur by Ascent. Ascent is surprised and disappointed with this announcement given the last communication between the parties was three weeks ago with Ascent confirming its forward process and timetables to achieve the possible combination, following which Ascent has been waiting for the Amur board to engage further on the proposal. Given that Ascent is expecting imminently the result of its €3.5 million+ arbitration claim against its JV partner in Slovenia, Ascent still believes that a combination of the two companies would be in the interest of both shareholder groups. Accordingly, Ascent is exploring the possibility to put forward a binding offer to the shareholders for the issued and to be issued share capital of Amur.お知らせ • Jun 02Ascent Resources Announces Intention to Bid for Amur MineralsThe board of directors of Ascent Resources Plc (AIM:AST) announced their intention to bid for the entire issued and to be issued share capital of Amur Minerals Corporation (AIM:AMC) following a period of protracted discussions with the Board of Amur. Ascent's vision is that Ascent and Amur would combine to form a larger, well funded and more liquid, entity combining Amur's cash (post the recently announced asset sale and subsequent dividend) with Ascent's ESG Metals project pipeline in LATAM, which typically have low geological risk and near term and sustainable cashflows, in addition to the significant upside exposure of Ascent's funded EUR 500+ million Energy Charter Treaty damages claim(the "Potential Combination"). Ascent submitted a non-binding indicative proposal to the Board of Amur in November 2022 to acquire 100% of the issued and to be issued share capital of Amur (post payment of its dividend as subsequently announced 24 May 2023) in a share-for-share exchange on a ratio of approximately 1 new Ascent share for every 21 Amur shares in issue (the "Exchange Ratio") (subject to the reservations set out below) (the "Indicative Proposal"). On the assumption that Amur only has assets of $5,000,000 in cash (post payment of dividend) and no further material liabilities, the indicative proposal is equivalent to a gross equity valuation of 6.1 pence per new Ascent share (based on an exchange rate of $1 = £0.8051). Despite multiple conversations with the Board of Amur and multiple follow up correspondence, the Company has as yet been unable to elicit a written response to their offer. The Indicative Proposal also included the intention to combine the skills of both executive teams, as well as other potential changes to the enlarged groups non-executive directors. It is intended that the enlarged group would have a majority of board directors from Ascent. The Exchange Ratio, based on Ascents volume weighted average share price of 3.6716 pence yesterday, being the last business day immediately prior to the date of this announcement, currently represents a value of approximately 0.175 pence per Amur share. At the current value of approximately 0.175 pence per Amur share implied by the Exchange Ratio, a potential offer, if made, when added to the 1.8 pence dividend to be paid by Amur would represent a premium of approximately: 7.3%. to the Amur closing price of 1.840 pence per share on 31 May 2023, being the last business day immediately prior to this announcement; 15.3%. to the monthly average volume weighted average price calculations for Amur shares over the three-month period starting on and including 1 March 2023, being 1.713 pence per share; and 47.5%. to the monthly average volume weighted average price for Amur shares over the six-month period starting on and including 1 December 2022, being 1.339 pence per share Under the terms of the Indicative Proposal, it is expected that Amur shareholders would own approximately 28.6%. of the enlarged group, and Ascent shareholders would own approximately 71.4%. of the enlarged group. Given the Indicative Proposal is currently proposed to be structured as an share-for-share exchange effected by either scheme of arrangement or plan of arrangement, Ascent is currently only minded to proceed with the Indicative Proposal on the pre-condition that a recommendation from the Amur Board is ultimately forthcoming.お知らせ • May 25Amur Minerals Corporation Announces Special Dividend, Payable on June 14, 2023Amur Minerals Corporation provide an update on the issuance of its special dividend of 1.8 pence per share. The special dividend is to be paid out of the funds received for the sale of its Russian Federation Kun-Manie nickel -copper asset. As the funds have been sourced from a non-sanctioned entity in Russia, payment of the dividend has required extraordinary non-typical enhanced governance approaches for implementation of payment. Shareholders of record at the close of business 2 June 2023 will be entitled to payment of the dividend projected to be 14 June 2023. The shares will go ex-dividend on 1 June 2023.収支内訳Amur Minerals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:AMMC.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Jun 230-32031 Mar 230-32031 Dec 220-32030 Jun 220-42031 Mar 220-32031 Dec 210-22030 Jun 210-13031 Mar 210-23031 Dec 200-33030 Sep 200-33030 Jun 200-32031 Mar 200-22031 Dec 190-22030 Sep 190-32030 Jun 190-32031 Mar 190-32031 Dec 180-32030 Sep 180-42030 Jun 180-42031 Mar 180-32031 Dec 170-12030 Sep 170-22030 Jun 170-22031 Mar 170-43031 Dec 160-64030 Sep 160-65030 Jun 160-65031 Mar 160-35031 Dec 150-14030 Sep 15033030 Jun 15072031 Mar 15032031 Dec 140-12030 Sep 140-42030 Jun 140-72031 Mar 140-52031 Dec 130-42030 Sep 130-22030 Jun 13002031 Mar 130-220質の高い収益: AMMC.Fは現在利益が出ていません。利益率の向上: AMMC.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: AMMC.Fは利益を出していないが、過去 5 年間で年間6.4%の割合で損失を削減してきた。成長の加速: AMMC.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: AMMC.Fは利益が出ていないため、過去 1 年間の収益成長をMetals and Mining業界 ( 82.4% ) と比較することは困難です。株主資本利益率高いROE: AMMC.Fは現在利益が出ていないため、自己資本利益率 ( -62.88% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/07 14:09終値2023/07/10 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CRISM Therapeutics Corporation これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Lord AshbourneEdison Investment ResearchDesmond KilaleaRBC Capital Markets
お知らせ • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024
お知らせ • Mar 31CRISM Therapeutics Corporation Provides Positive Update Regarding Its Clinical Trial Authorisation ApplicationCRISM Therapeutics Corporation provided a positive update regarding its clinical trial authorisation application to evaluate irinotecan ChemoSeed in patients with high grade glioma. CRISM has been working with the Medicines and Healthcare products Regulatory Agency to finalise the design of the first in-human trial of ChemoSeed and is pleased to confirm it has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed. The written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately PS400,000 to conduct the toxicology studies. In addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in first quarter 2025 and to begin clinical trials of ChemoSeed in fourth quarter 2025, subject to MHRA and other external regulatory organizations meeting expected review times. The Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify.
お知らせ • Mar 28CRISM Therapeutics Corporation Announces Grant Awarded by Innovate UKCRISM Therapeutics Corporation announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the "Project"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas. The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology ("docetaxel ChemoSeed") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment. Docetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect. The Project, which will take about 12 months, is designed to deliver: A functional prototype of the implantable device; Pre-clinical validation data demonstrating safety and efficacy; IP protection through patents for core innovations; Scalable manufacturing protocols for commercialisation. The outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy. The total cost of the Project is £152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of £96,106, which represents 63% of the total cost. The remaining £56,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed.
お知らせ • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024
お知らせ • May 15Amur Minerals Corporation, Annual General Meeting, May 29, 2024Amur Minerals Corporation, Annual General Meeting, May 29, 2024. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
お知らせ • Nov 13Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023, at 10:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom
お知らせ • Sep 25Amur Minerals Corporation Announces Special DividendAmur Minerals Corporation announced to pay a one-time special dividend of 1.8 pence per ordinary share within 90 days of receipt of the completion payment.
お知らせ • Sep 07Amur Minerals Announces Suspension of Trading on AIMAmur Minerals Corporation confirmed that trading in the Company's shares on AIM will be suspended with effect from 7.30 a.m. BST 7 September 2023. As stated in the Company's notification of 6 March 2023, following the disposal of the Company's AO Kun-Manie subsidiary, Amur became classified as an AIM Rule 15 cash shell from that date, and as such was required to make an acquisition or acquisitions which would constitute a reverse takeover under Rule 14 of the AIM Rules for Companies, or be re-admitted on AIM as an investing company under the AIM Rules on or before the date falling six months from 6 March 2023. As neither a reverse takeover nor readmission to trading on AIM as an investing company have been completed, trading in the Company's shares on AIM will now be suspended on7 September 2023. Trading will remain suspended until the completion of a reverse takeover, which requires the publication of an admission document and the approval of such a transaction at a General Meeting of the Company, or the Company is readmitted to trading on AIM as an investing company. If no such transaction is completed within six months, the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41. There can be no assurance that the Company will be able to complete a reverse takeover during the six-month suspension period. The board of Amur continues to review a number of reverse takeover opportunities. Further announcements will be made as appropriate.
お知らせ • Aug 10Amur Minerals Corporation Announces Cessation of Discussions with Ascent Resources PlcAscent Resources Plc (AIM:AST) ("Ascent" or, the "Company"), noted Amur Minerals Corporation (AIM:AMC) ("Amur") announcement, regarding the cessations of discussions regarding thenon-binding indicative proposal of a possible share offer for the entire issued and to be issued share capital of Amur by Ascent. Ascent is surprised and disappointed with this announcement given the last communication between the parties was three weeks ago with Ascent confirming its forward process and timetables to achieve the possible combination, following which Ascent has been waiting for the Amur board to engage further on the proposal. Given that Ascent is expecting imminently the result of its €3.5 million+ arbitration claim against its JV partner in Slovenia, Ascent still believes that a combination of the two companies would be in the interest of both shareholder groups. Accordingly, Ascent is exploring the possibility to put forward a binding offer to the shareholders for the issued and to be issued share capital of Amur.
お知らせ • Jun 02Ascent Resources Announces Intention to Bid for Amur MineralsThe board of directors of Ascent Resources Plc (AIM:AST) announced their intention to bid for the entire issued and to be issued share capital of Amur Minerals Corporation (AIM:AMC) following a period of protracted discussions with the Board of Amur. Ascent's vision is that Ascent and Amur would combine to form a larger, well funded and more liquid, entity combining Amur's cash (post the recently announced asset sale and subsequent dividend) with Ascent's ESG Metals project pipeline in LATAM, which typically have low geological risk and near term and sustainable cashflows, in addition to the significant upside exposure of Ascent's funded EUR 500+ million Energy Charter Treaty damages claim(the "Potential Combination"). Ascent submitted a non-binding indicative proposal to the Board of Amur in November 2022 to acquire 100% of the issued and to be issued share capital of Amur (post payment of its dividend as subsequently announced 24 May 2023) in a share-for-share exchange on a ratio of approximately 1 new Ascent share for every 21 Amur shares in issue (the "Exchange Ratio") (subject to the reservations set out below) (the "Indicative Proposal"). On the assumption that Amur only has assets of $5,000,000 in cash (post payment of dividend) and no further material liabilities, the indicative proposal is equivalent to a gross equity valuation of 6.1 pence per new Ascent share (based on an exchange rate of $1 = £0.8051). Despite multiple conversations with the Board of Amur and multiple follow up correspondence, the Company has as yet been unable to elicit a written response to their offer. The Indicative Proposal also included the intention to combine the skills of both executive teams, as well as other potential changes to the enlarged groups non-executive directors. It is intended that the enlarged group would have a majority of board directors from Ascent. The Exchange Ratio, based on Ascents volume weighted average share price of 3.6716 pence yesterday, being the last business day immediately prior to the date of this announcement, currently represents a value of approximately 0.175 pence per Amur share. At the current value of approximately 0.175 pence per Amur share implied by the Exchange Ratio, a potential offer, if made, when added to the 1.8 pence dividend to be paid by Amur would represent a premium of approximately: 7.3%. to the Amur closing price of 1.840 pence per share on 31 May 2023, being the last business day immediately prior to this announcement; 15.3%. to the monthly average volume weighted average price calculations for Amur shares over the three-month period starting on and including 1 March 2023, being 1.713 pence per share; and 47.5%. to the monthly average volume weighted average price for Amur shares over the six-month period starting on and including 1 December 2022, being 1.339 pence per share Under the terms of the Indicative Proposal, it is expected that Amur shareholders would own approximately 28.6%. of the enlarged group, and Ascent shareholders would own approximately 71.4%. of the enlarged group. Given the Indicative Proposal is currently proposed to be structured as an share-for-share exchange effected by either scheme of arrangement or plan of arrangement, Ascent is currently only minded to proceed with the Indicative Proposal on the pre-condition that a recommendation from the Amur Board is ultimately forthcoming.
お知らせ • May 25Amur Minerals Corporation Announces Special Dividend, Payable on June 14, 2023Amur Minerals Corporation provide an update on the issuance of its special dividend of 1.8 pence per share. The special dividend is to be paid out of the funds received for the sale of its Russian Federation Kun-Manie nickel -copper asset. As the funds have been sourced from a non-sanctioned entity in Russia, payment of the dividend has required extraordinary non-typical enhanced governance approaches for implementation of payment. Shareholders of record at the close of business 2 June 2023 will be entitled to payment of the dividend projected to be 14 June 2023. The shares will go ex-dividend on 1 June 2023.